The burden of neurological diseases in Europe: an analysis for the Global Burden of Disease Study 2017.

BACKGROUND Neurological disorders account for a large and increasing health burden worldwide, as shown in the Global Burden of Diseases (GBD) Study 2016. Unpacking how this burden varies regionally and nationally is important to inform public health policy and prevention strategies. The population in the EU is older than that of the WHO European region (western, central, and eastern Europe) and even older than the global population, suggesting that it might be particularly vulnerable to an increasing burden of age-related neurological disorders. We aimed to compare the burden of neurological disorders in the EU between 1990 and 2017 with those of the WHO European region and worldwide. METHODS The burden of neurological disorders was calculated for the year 2017 as incidence, prevalence, mortality, disability-adjusted life-years (DALYs), years of life lost, and years lived with disability for the countries in the EU and the WHO European region, totally and, separately. Diseases analysed were Alzheimer's disease and other dementias, epilepsy, headache (migraine and tension-type headache), multiple sclerosis, Parkinson's disease, brain cancer, motor neuron diseases, neuroinfectious diseases, and stroke. Data are presented as totals and by sex, age, year, location and socio-demographic context, and shown as counts and rates. FINDINGS In 2017, the total number of DALYs attributable to neurological disorders was 21·0 million (95% uncertainty interval 18·5-23·9) in the EU and 41·1 million (36·7-45·9) in the WHO European region, and the total number of deaths was 1·1 million (1·09-1·14) in the EU and 1·97 million (1·95-2·01) in the WHO European region. In the EU, neurological disorders ranked third after cardiovascular diseases and cancers representing 13·3% (10·3-17·1) of total DALYs and 19·5% (18·0-21·3) of total deaths. Stroke, dementias, and headache were the three commonest causes of DALYs in the EU. Stroke was also the leading cause of DALYs in the WHO European region. During the study period we found a substantial increase in the all-age burden of neurodegenerative diseases, despite a substantial decrease in the rates of stroke and infections. The burden of neurological disorders in Europe was higher in men than in women, peaked in individuals aged 80-84 years, and varied substantially with WHO European region and country. All-age DALYs, deaths, and prevalence of neurological disorders increased in all-age measures, but decreased when using age-standardised measures in all but three countries (Azerbaijan, Turkmenistan, and Uzbekistan). The decrease was mostly attributed to the reduction of premature mortality despite an overall increase in the number of DALYs. INTERPRETATION Neurological disorders are the third most common cause of disability and premature death in the EU and their prevalence and burden will likely increase with the progressive ageing of the European population. Greater attention to neurological diseases must be paid by health authorities for prevention and care. The data presented here suggest different priorities for health service development and resource allocation in different countries. FUNDING European Academy of Neurology.

[1]  E. Beghi,et al.  The epidemiology of epilepsy in Europe – a systematic review , 2005, European journal of neurology.

[2]  H. Sørensen Global burden of neurological disorders: challenges and opportunities with the available data , 2019, The Lancet Neurology.

[3]  L. Bodin,et al.  Occupational Exposures and Neurodegenerative Diseases—A Systematic Literature Review and Meta-Analyses , 2019, International journal of environmental research and public health.

[4]  G. Comi,et al.  Evolving concepts in the treatment of relapsing multiple sclerosis , 2017, The Lancet.

[5]  E. Cardis,et al.  Environmental Factors and the Risk of Brain Tumours in Young People: A Systematic Review , 2019, Neuroepidemiology.

[6]  Ashutosh Kumar Singh,et al.  Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 , 2016, Lancet.

[7]  J. Wardlaw,et al.  Thrombolysis for acute ischaemic stroke. , 2014, The Cochrane database of systematic reviews.

[8]  Martin McKee,et al.  Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. , 2013, JAMA.

[9]  G. Jiang,et al.  Mobile phone use and glioma risk: A systematic review and meta-analysis , 2017, PloS one.

[10]  Mohammad Hossein Khosravi,et al.  Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2017, Lancet.

[11]  Yoshihiro Kokubo,et al.  Global, regional, and national burden of Parkinson's disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2018, The Lancet Neurology.

[12]  A. Wimo,et al.  The global prevalence of dementia: A systematic review and metaanalysis , 2013, Alzheimer's & Dementia.

[13]  Gail Davey Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2017 .

[14]  Haomiao Jia,et al.  Burden of disease due to sleep duration and sleep problems in the elderly , 2018, Sleep health.

[15]  Anders Larsson,et al.  Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 , 2017, The Lancet Neurology.

[16]  Gretchen A. Stevens,et al.  National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants , 2011, The Lancet.

[17]  Mirjam Kretzschmar,et al.  Disability weights for the Global Burden of Disease 2013 study. , 2015, The Lancet. Global health.

[18]  E Ray Dorsey,et al.  The Parkinson Pandemic-A Call to Action. , 2018, JAMA neurology.

[19]  Alan D. Lopez,et al.  Global burden of disease and risk factors , 2006 .

[20]  Eyal Oren,et al.  Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2017, The Lancet. Neurology.

[21]  Ashutosh Kumar Singh,et al.  Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 , 2016, Lancet.

[22]  Ivy Shiue,et al.  Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2018, The Lancet Neurology.

[23]  Seyyed Nasrollah Hosseini,et al.  The global burden of childhood and adolescent cancer in 2017: an analysis of the Global Burden of Disease Study 2017 , 2019, The Lancet. Oncology.

[24]  Gretchen A. Stevens,et al.  National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5·4 million participants , 2011, The Lancet.

[25]  Gretchen A. Stevens,et al.  National, regional, and global trends in serum total cholesterol since 1980: systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 3·0 million participants , 2011, The Lancet.

[26]  Joav Merrick,et al.  Neurological Disorders: Public Health Challenges , 2007 .

[27]  G. Deuschl,et al.  β-adrenoreceptors and the risk of Parkinson's disease , 2020, The Lancet Neurology.

[28]  Ivy Shiue,et al.  Global burden of stroke and risk factors in 188 countries, during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2016, The Lancet Neurology.

[29]  David H. Miller,et al.  Diagnosis of multiple sclerosis: progress and challenges , 2017, The Lancet.

[30]  K. Innes,et al.  Prevalence of restless legs syndrome in North American and Western European populations: a systematic review. , 2011, Sleep medicine.

[31]  J. Perlmutter,et al.  Neurologist care in Parkinson disease , 2011, Neurology.

[32]  Reza Ghadimi Population and fertility by age and sex for 195 countries and territories, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2018, Lancet.

[33]  B. Kissela,et al.  Temporal trends in acute stroke management. , 2013, Stroke.

[34]  M. Ezzati,et al.  National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants , 2011, The Lancet.

[35]  O. Rascol,et al.  Experience of care for Parkinson's disease in European countries: a survey by the European Parkinson's Disease Association , 2018, European journal of neurology.